Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

Botrus Gehan; Raman Puneet; Oliver ThomasBekaii-Saab Tanios

首页> 外文期刊>Expert opinion on investigational drugs >Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

【24h】

Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

机译：Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Introduction

著录项

来源
《Expert opinion on investigational drugs》 |2021年第6期|309-316|共8页
作者
Botrus Gehan; Raman Puneet; Oliver ThomasBekaii-Saab Tanios;
展开▼
作者单位

Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA;

Mayo Clin Arizona, Dept Internal Med, Scottsdale, AZ USA;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
Cholangiocarcinoma; fgfr; chemotherapy; bgj398; infigratinib;

客服邮箱：kefu@zhangqiaokeyan.com

客服微信
服务号

Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

摘要

著录项

相关主题

期刊订阅